Portfolio News Vittoria Biotherapeutics

Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies

By WebmasterNovember 14, 2023December 12th, 2024No Comments

Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies

Funds to support advancement of lead candidate, VIPER-101, to the clinic

Previous PostSIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma
Next PostVESTECK, Inc. "it is always someone's mom or dad, brother or sister."